The prognostic significance of BAP1, NF2 and CDKN2A in malignant peritoneal mesothelioma

BAP1 Immunohistochemistry and p16 FISH to Separate Benign From Malignant Mesothelial Proliferations

(2015) Brandon S. Sheffield et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma

(2015) Masaki Nasu et al.   Journal of Thoracic Oncology

Loss of expression of BAP1 predicts longer survival in mesothelioma

(2015) Mahtab Farzin et al.   PATHOLOGY

Whole-Exome Sequencing Reveals Frequent Genetic Alterations in BAP1, NF2, CDKN2A, and CUL1 in Malignant Pleural Mesothelioma

(2014) G. Guo et al.   CANCER RESEARCH

Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival

(2014) Francine Baumann et al.   CARCINOGENESIS

Malignant Peritoneal Mesothelioma: Prognostic Factors and Oncologic Outcome Analysis

(2013) Deepa Magge et al.   ANNALS OF SURGICAL ONCOLOGY

p16Deletion in Sarcomatoid Tumors of the Lung and Pleura

(2013) Naobumi Tochigi et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Clinical Characteristics of Patients with Malignant Pleural Mesothelioma Harboring Somatic BAP1 Mutations

(2013) Marjorie G. Zauderer et al.   Journal of Thoracic Oncology

Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma

(2013) H. Richard Alexander et al.   SURGERY

Diagnostic Usefulness of p16/CDKN2A FISH in Distinguishing Between Sarcomatoid Mesothelioma and Fibrous Pleuritis

(2012) Di Wu et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

A new standard of care for the management of peritoneal surface malignancy

(2011) F. Mohamed et al.   Current Oncology

The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma

(2011) Matthew Bott et al.   NATURE GENETICS

A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*

(2010) Tristan D. Yan et al.   CANCER

FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma

(2010) C. T.-S. Chung et al.   JOURNAL OF CLINICAL PATHOLOGY

CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival

(2010) Alyssa M Krasinskas et al.   MODERN PATHOLOGY

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience

(2009) Tristan D. Yan et al.   JOURNAL OF CLINICAL ONCOLOGY

Malignant Pleural Mesothelioma

(2009) Anne S. Tsao et al.   JOURNAL OF CLINICAL ONCOLOGY

A Conditional Mouse Model for Malignant Mesothelioma

(2008) Johan Jongsma et al.   CANCER CELL

Peritoneal Mesothelioma

(2008) Mary E. Hesdorffer et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Consensus statement on peritoneal mesothelioma

(2008) Marcello Deraco et al.   JOURNAL OF SURGICAL ONCOLOGY

Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma

(2008) Naruyuki Kobayashi et al.   LUNG CANCER

Functional inactivation of NF2/merlin in human mesothelioma

(2008) Claudio Thurneysen et al.   LUNG CANCER

Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas

(2008) Simion Chiosea et al.   MODERN PATHOLOGY

Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas

(2008) Sanja Dacic et al.   VIRCHOWS ARCHIV